Bharat Parenter. Q1 FY27 Results (BSE: 541096)
Signal: Loss widened
The read
The trajectory is a transition rather than a clean recovery: consolidated revenue fell 19.2% YoY to ₹9373.65 lakh and EBITDA margin fell 277bps to 9.1%, but parent profit attributable to owners turned positive at ₹100.79 lakh; the key inflection is Innoxel's planned Q2FY27 commercial ramp, which must absorb its ₹630 lakh quarterly depreciation and ₹230 lakh finance-cost burden.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹93.74 Cr | -19.2% | -5.9% |
| EBIT | ₹0.96 Cr | -88.9% | |
| Net profit | ₹-3.56 Cr | -308.4% | |
| EPS | ₹-5.17 | N/A | |
| EBIT margin | 9.1% |
P&L walk
Consolidated revenue declined 19.2% YoY to ₹9373.65 lakh, but gross margin expanded 995bps to 50.6% on mix and inventory effects; operating expenses rose 16.5% to ₹3890 lakh, reducing EBITDA 38.0% to ₹853.45 lakh and leaving a ₹356.33 lakh loss after ₹868.67 lakh depreciation and ₹245.23 lakh finance cost.
Segments
Trading of pharma products generated ₹98 lakh revenue but ₹1853.59 lakh segment result, while CDMO generated ₹2946.18 lakh revenue and a ₹361.47 lakh segment loss; the group outcome is therefore being dragged by CDMO fixed costs despite rapid subsidiary revenue growth.
Key positives
- Parent standalone business remained profitable at ₹365.71 lakh PAT despite revenue falling 41.2% YoY, supported by operating expenses down 6.0% and finance costs down 51.0%.
- Varenyam Healthcare revenue rose 52.2% YoY to ₹2510 lakh and EBITDA margin expanded 270bps to 12.4%, reversing its Q4FY26 loss.
- Order book stood at ₹17100 lakh, covering approximately 80%–85% of the revenue required for the remaining nine months of FY27.
- Standalone borrowings declined 46% YoY to ₹1690 lakh and trade receivables fell 32% YoY to ₹11860 lakh.
Key concerns
- Consolidated revenue declined 19.2% YoY to ₹9373.65 lakh and EBITDA fell 38.0% to ₹853.45 lakh as standalone revenue lost the prior-year institutional-order benefit.
- Innoxel reported a ₹1040 lakh PAT loss despite ₹2140 lakh revenue, with ₹630 lakh depreciation and ₹230 lakh finance cost creating a fixed-charge burden before commercial CMO supply.
- Consolidated EBITDA margin contracted 277bps YoY to 9.1% because operating expenses rose 16.5% while gross profit was broadly flat.
- The consolidated loss of ₹356.33 lakh was driven by ₹457.12 lakh loss attributable to non-controlling interests, despite ₹100.79 lakh profit attributable to owners.
Research and educational content only. Not investment advice.